title: [Implant exposure after viscocanalostomy with reticulated hyaluronic acid (SK-GEL)].
abstract: BACKGROUND
  Lately, the application of intrascleral implants has been increasingly discussed to improve success rates of nonpenetrating surgery for the treatment of open-angle glaucoma.
  
  
  METHODS
  A 36-year-old male patient with medically uncontrolled pigmentary glaucoma underwent viscocanalostomy with intrascleral implantation of reticulated hyaluronic acid (SK-GEL) in his right eye.
  
  
  RESULTS
  The immediate postoperative course was unremarkable with control of intraocular pressure without additional glaucoma medications. At first follow-up, 2 weeks post surgery, conjunctival dehiscence with partial extrusion and exposure of the reticulated hyaluronic acid implant was observed. Under topical tobramycin ointment a gradual limbal readaptation of the conjunctiva over the surface of the exposed parts of the implant with formation of a filtration bleb was noted. Therefore, surgical revision remained unnecessary.
  
  
  CONCLUSIONS
  Implant exposure following nonpenetrating antiglaucomatous surgery is a specific complication, which can appear whenever intrascleral implants are used. Depending on the local situation nonsurgical treatment may be successful.
authors.affiliation: Zentrum für Augenheilkunde, Universität, Köln. aia18@uni-koeln.de
authors.forename: C
authors.initials: C
authors.lastname: Lüke
authors.forename: T S
authors.initials: TS
authors.lastname: Dietlein
authors.forename: S
authors.initials: S
authors.lastname: Roters
authors.forename: P C
authors.initials: PC
authors.lastname: Jacobi
authors.forename: W
authors.initials: W
authors.lastname: Konen
authors.forename: G K
authors.initials: GK
authors.lastname: Krieglstein
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D005500:Follow-Up Studies; D020327:Glaucoma Drainage Implants; D005902:Glaucoma, Open-Angle / Q000601:surgery*; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage* / Q000009:adverse effects; D007429:Intraocular Pressure; D008297:Male; D009824:Ointments; D013997:Time Factors; D014031:Tobramycin / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D009824:Ointments; D006820:Hyaluronic Acid; D014031:Tobramycin